Want to see IN:BLISSGVS full AI Analyst Report?
BLISSGVS Stock Chart & Stats
₹144.75
-₹6.85(-3.92%)
At close: 4:00 PM EST
₹144.75
-₹6.85(-3.92%)
Day’s Range― - ―
52-Week Range₹118.35 - ₹552.90
Previous CloseN/A
Volume571.01K
Average Volume (3M)104.36K
Market Cap
₹55.54B
Enterprise Value₹50.10B
Total Cash (Recent Filing)₹1.89B
Total Debt (Recent Filing)₹217.50M
Price to Earnings (P/E)43.2
Beta1.28
Next Earnings
Aug 04, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.28%
Share Statistics
EPS (TTM)12.13
Shares Outstanding106,056,220
10 Day Avg. Volume77,644
30 Day Avg. Volume104,358
Financial Highlights & Ratios
PEG Ratio0.36
Price to Book (P/B)2.03
Price to Sales (P/S)2.61
P/FCF Ratio29.58
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Conservative, Improving Balance SheetA materially reduced debt load and rising equity/assets provide durable financial flexibility. This lowers refinancing and liquidity risk, supports investment or M&A optionality, and makes the firm more resilient to industry cycles over the next 2–6 months.
Steady Revenue Growth TrendConsistent mid-to-high single-digit revenue growth indicates stable demand and expanding market penetration. Over the medium term this supports predictable top-line expansion, better operating leverage potential, and planning for capacity or marketing investments.
Improving Cash Generation And FCF ReboundA rebound to positive free cash flow demonstrates renewed cash-generating capacity, enabling reinvestment, debt reduction, or shareholder returns. While conversion has varied historically, current FCF strength improves near-term financial stability and funding self-sufficiency.
Bears Say
Volatile Margins And Earnings HistoryPronounced past swings in margins and earnings signal that profitability is sensitive to product mix, pricing, or cost variability. This raises execution risk for sustaining margin expansion and complicates forecasting of sustainable earnings power over the coming months.
Choppy Cash Conversion And Working-capital SwingsLarge year-to-year free cash flow swings point to working-capital or capex variability that can strain liquidity during adverse periods. This unpredictability can impede consistent deleveraging, capital allocation discipline, and reliable reinvestment planning.
Exposure To Pricing Pressure In GenericsReliance on generic/formulation sales exposes margins to structural pricing pressure and competition. Over the medium term, commoditization risk can constrain margin expansion and require continuous cost or differentiation investments to protect profitability.
Bliss Gvs Pharma Limited News
BLISSGVS FAQ
What was Bliss Gvs Pharma Limited’s price range in the past 12 months?
Bliss Gvs Pharma Limited lowest stock price was ₹118.35 and its highest was ₹552.90 in the past 12 months.
What is Bliss Gvs Pharma Limited’s market cap?
Bliss Gvs Pharma Limited’s market cap is ₹55.54B.
When is Bliss Gvs Pharma Limited’s upcoming earnings report date?
Bliss Gvs Pharma Limited’s upcoming earnings report date is Aug 04, 2026 which is in 23 days.
How were Bliss Gvs Pharma Limited’s earnings last quarter?
Bliss Gvs Pharma Limited released its earnings results on May 12, 2026. The company reported ₹3.363 earnings per share for the quarter, beating the consensus estimate of N/A by ₹3.363.
Is Bliss Gvs Pharma Limited overvalued?
According to Wall Street analysts Bliss Gvs Pharma Limited’s price is currently Overvalued.
Does Bliss Gvs Pharma Limited pay dividends?
Bliss Gvs Pharma Limited pays a Annually dividend of ₹1 which represents an annual dividend yield of 0.28%. See more information on Bliss Gvs Pharma Limited dividends here
What is Bliss Gvs Pharma Limited’s EPS estimate?
Bliss Gvs Pharma Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Bliss Gvs Pharma Limited have?
Bliss Gvs Pharma Limited has 106,056,220 shares outstanding.
What happened to Bliss Gvs Pharma Limited’s price movement after its last earnings report?
Bliss Gvs Pharma Limited reported an EPS of ₹3.363 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 0.59%.
Which hedge fund is a major shareholder of Bliss Gvs Pharma Limited?
Currently, no hedge funds are holding shares in IN:BLISSGVS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Bliss Gvs Pharma Limited
Established in 1984 and headquartered in Mumbai, India, Bliss GVS Pharma Limited specializes in the development, manufacturing, and distribution of a comprehensive array of pharmaceutical products. The company's pharmaceutical portfolio includes an extensive range of dosage forms, such as oral solids (tablets, capsules), various liquid and injectable preparations, topical applications (creams, gels), and advanced drug delivery systems like transdermal patches. Beyond conventional medicines, Bliss GVS also offers a diverse selection of other healthcare and personal care items, including balms, lotions, shampoos, and over-the-counter remedies. Their therapeutic focus is equally broad, encompassing solutions for anti-infectives, pain management, gastrointestinal issues, anti-malarials, dermatological conditions, nutritional support, and a wide variety of other wellness and hygiene products, including medicated and cosmetic soaps. The company actively engages in international exports, extending its market presence beyond India.
Technical Analysis
Bajaj Healthcare Ltd
―
Hester Biosciences Limited
―
Jagsonpal Pharmaceuticals Ltd.
―
Syncom Formulation (India) Ltd.
―
Windlas Biotech Ltd.
―